[1]CurrentPatentAssignee:ANHUIYELLENPHARMACEUTICAL-CN107501243,2017,ALocationinpatent:Paragraph0021
[2]CurrentPatentAssignee:CIPLALTD-WO2016/102979,2016,A1Locationinpatent:Page/Pagecolumn27
[3]CurrentPatentAssignee:JIANGSUSULIFINECHEMICAL-CN105753844,2016,ALocationinpatent:Paragraph0044;0045
[4]CurrentPatentAssignee:VIATRISINC-WO2016/178250,2016,A1Locationinpatent:Page/Pagecolumn26
[5]CurrentPatentAssignee:LAURUSLABSLIMITED-WO2017/21904,2017,A1Locationinpatent:Page/Pagecolumn24;25
[6]CurrentPatentAssignee:SICHUANTONGSHENGBIOPHARMACEUTICAL-CN106256825,2016,ALocationinpatent:Paragraph0071-0073
[7]CurrentPatentAssignee:GLENMARKPHARMACEUTICALSLTD-WO2018/15847,2018,A1Locationinpatent:Paragraph0130;0131
[8]CurrentPatentAssignee:MSNLABORATORIESPRIVATELIMITED-WO2018/134842,2018,A1Locationinpatent:Page/Pagecolumn36-37
[1]Yu,Guang-Xiang;Lin,Chien-Hsiang;Liu,You-Xuan;Yi,Rong-Huei;Chen,Guan-Yu;Lu,Chin-Wei;Su,Hai-Ching[Chemistry-AEuropeanJournal,2019,vol.25,#60,p.13748-13758]
[1]CurrentPatentAssignee:NANTONGCHANGYOUMEDICINETECH-CN110878090,2020,A
[1]CurrentPatentAssignee:NANTONGCHANGYOUMEDICINETECH-CN110878090,2020,A
[1]CurrentPatentAssignee:NANTONGCHANGYOUMEDICINETECH-CN110878090,2020,ALocationinpatent:Paragraph0027;0032-0033
Title: Min Gao, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010 May 6;465(7294):96-100.
Title: David B Ascher, et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep. 2014 Apr 23;4:4765.
Title: Tomomi Furihata, et al. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother. 2014 Aug;58(8):4555-64.
Title: Seung-Hoon Lee, et al. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice. Sci Rep. 2018 Aug 20;8(1):12469.